H. Lundbeck A/S- (NASDAQ:HLUYY) has earned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Zacks has also assigned H. Lundbeck A/S- an industry rank of 77 out of 265 based on the ratings given to related companies.

HLUYY has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of H. Lundbeck A/S- from a “hold” rating to a “strong-buy” rating and set a $69.00 price objective on the stock in a research report on Friday, August 11th. Deutsche Bank AG cut shares of H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Friday, July 28th.

H. Lundbeck A/S- (NASDAQ HLUYY) traded up 0.83% during trading on Wednesday, hitting $63.07. The stock had a trading volume of 354 shares. H. Lundbeck A/S- has a 12-month low of $31.00 and a 12-month high of $63.62. The firm has a market cap of $12.44 billion and a P/E ratio of 39.74. The stock’s 50 day moving average price is $59.78 and its 200 day moving average price is $51.34.

TRADEMARK VIOLATION WARNING: “Zacks: H. Lundbeck A/S- (HLUYY) Given Average Recommendation of “Hold” by Brokerages” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.watchlistnews.com/zacks-h-lundbeck-as-hluyy-given-average-recommendation-of-hold-by-brokerages/1532628.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with Analyst Ratings Network's FREE daily email newsletter.